ASH 2018: New data presented on synergistic action of LIMK inhibitors with BCR-ABL TKIs

At the 60th American Society of Hematology Congress, Pr Thorsten Braun presented the work performed by the Leukemia Translational Laboratory, Saint Louis Hospital , Paris, on selective LIM Kinase 1/2 inhibitors for combination treatment of BCR-ABL1 Acute Lymphoblastic Leukemia.

This new data includes positive results from in vitro experiments and in vivo models, obtained when combining administration of CEL_Amide with BCR-ABL1 Tyrosine Kinase Inhibitors including nilotinib.

It reinforces the rationale for looking into LIM Kinase inhibition as synergistic therapeutic agents with TKIs targeting TKRs upstream of the Rho-GTPase pathway, such as FLT3, C-KIT and BCR-ABL.

The ASH 2018 Poster can downloaded here Poster BCR-ABl LIMK ASH 2018

CELLIPSE is developing selective and highly potent LIM Kinase small molecule inhibitors.  We aim to bring new targeted therapies against cancer indications with poor overall prognosis and high medical need such as Acute Myeloïd Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and other Myeloproliferative Neoplasms.

CEL_Amide is CELLIPSE’s Lead Candidate for developing and introducing in the clinic first-in-class LIM Kinase inhibitors.